3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
2
Neoplasms
2
Endometrial Neoplasms
2
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
Pemetrexed
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Specimen Handling
4
Mastectomy, Segmental
4
Cisplatin
4
Bevacizumab
4
durvalumab
2
Platinum
2
Biopsy
2
tislelizumab
1
osimertinib
1
methyl-4-fluoro-4-deoxyglucose
1
methoxyamine
1
fludarabine phosphate
1
devimistat
1
dehydroftorafur
1
defactinib
1
dapagliflozin
1
capmatinib
1
aflutinib
1
Standard of Care
1
Smoking Devices
1
Radiotherapy
1
Radiation
1
RO5126766
1
Practice Guidelines as Topic
1
Observation
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma of Lung
×
AZD5305
×
Clear all
NCT05797168
2026-06-03
FONTANA
AstraZeneca
Phase 1/2
Recruiting
506 enrolled